Foghorn Therapeutics Inc. Common Stock FHTX
$4.92
+1.03%
at last close
Market Cap$292.18 million
P/E Ratio—
Div Yield—
Volume266.0K
52-Week Range
$3.27$7.61
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $11.67 (+137.1% upside)
Key Stats
- Today's Range
- $4.70 – $5.00
- 50-Day Range
- $3.98 – $7.61
- 52-Week Range
- $3.27 – $7.61
- Volume
- 266K shs
- Average Volume
- 332K shs
- Market Cap
- $292.18 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -3.61
- Price / Sales
- 7.95
Short Interest
- Short Interest
- 0.03%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $36.74 million
- Net Income
- $-64,579,000
- Net Margin
- -175.78%
- Return on Equity
- 79.69%
- Debt-to-Equity
- —
About Foghorn Therapeutics Inc. Common Stock
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Related Stocks
Compare head-to-head: FHTX vs LLY·FHTX vs JNJ·FHTX vs ABBV·FHTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.